Endo Ventures Limited (EVL), a subsidiary of Endo International plc, agreed with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, will commercialize his TLC product, TLC599, which is under investigation. TLC599 is an injectable compound in Phase III development for the treatment of knee osteoarthritis knee pain.
Pfizer and Acuitas Therapeutics entered into a Development and Options Agreement. This gives Pfizer the option to license Aquinas lipid nanoparticle (LNP) technology non-exclusively for up to 10 vaccine targets or therapeutics development.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4073
Published Date: May 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The rising prevalence of cancer globally, and the increasing application of liposomes as a drug delivery system are some of the major factors anticipated to drive market growth.
The market size of capsaicin is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2035.
North America is estimated to create notable growth opportunities for market growth over the forecast period.
The major players in the market are Sciences, Inc., Celsion Corporation, Ipsen Pharma, Pacira Pharmaceuticals, Inc., Novartis AG, CordenPharma International, FUJIFILM Toyama Chemical Co., Ltd., and Others.
The liposomal doxorubicin segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.